Osteopontin Expression Is Associated with the Poor Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy

Abstract

Background The osteopontin has been involved in therapeutic resistance in a variety of cancers. But, the significance of osteopontin expression on the prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC) receiving chemoradiotherapy is unclear. Methods In 80 patients with locally advanced ESCC receiving preoperative chemoradiotherapy between 1999 and 2012, osteopontin expression was evaluated by immunohistochemistry and correlated with treatment outcome. The functional role of osteopontin in ESCC cell lines was determined by osteopontin-mediated siRNA. Results Osteopontin expression and clinical T4 classification were significantly associated with poor pathological complete response. Univariate analyses demonstrated that osteopontin overexpression and clinical T classification, T4, were significantly associated with worse overall survival and disease-free survival. In multivariate comparison, osteopontin overexpression and clinical T classification, T4, represented the independent adverse prognosticator. In ESCC cell lines, endogenous osteopontin depletion by osteopontin-mediated siRNA increased sensitivity to cisplatin. Osteopontin expression is independently correlated with the response of chemoradiotherapy and prognosis of patients with locally advanced ESCC receiving preoperative chemoradiotherapy. Conclusions Our results suggest that osteopontin may be a potential therapeutic target for patients with ESCC treated with preoperative chemoradiotherapy.

Identification of four genes and biological characteristics of esophageal squamous cell carcinoma by integrated bioinformatics analysis

“…Further analysis demonstrated that differentially expressed immune signatures in ESCC might be crucial to tumorigenesis and development by activating T cell and NF-kappa B signaling pathways [ 36 ]. Recently, SPP1 expression was reported to be associated with poor prognosis in locally advanced ESCC patients receiving preoperative chemoradiotherapy [ 37 ]. A meta-analysis involving 811 patients showed that overexpression of SPP1 might be a promising independent prognostic risk factor for ESCC patients in China and Japan [ 9 ].…”

Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy

“…The clinical staging was determined according to image examinations including a computed tomography (CT) scan of the abdomen and chest, endoscopic ultrasound (EUS), and/or positron emission tomography (PET) scan. The protocol of neoadjuvant chemoradiotherapy followed by esophagectomy was previously described [14,27]. Overall survival (OS) was computed from diagnosis date until the death date or the last follow-up.…”

An actin-binding protein ESPN is an independent prognosticator and regulates cell growth for esophageal squamous cell carcinoma

“…Thus, the treatment outcome of the patients with ESCC receiving esophagectomy alone remains poor [2, 4, 5]. While the efficacy of preoperative therapy is relatively clear, the effect of postoperative adjuvant therapy remains controversial [14, 15]. Several studies of post-operative adjuvant therapy have been performed in an attempt to improve upon the survival rate achieved with esophagectomy alone, but the results are inconclusive.…”